SecBot SecBot
8-K ·Filed Oct 29, 2026

MRMD

MARIMED INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 1h ago SEC0001522767-26-000213
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for board decision on whether to implement the reverse split and at what ratio; a decision to proceed could signal a move toward a national exchange listing, while abandonment would leave the stock on OTCQB.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

MariMed Inc. stockholders approved a reverse stock split at a ratio between 1-for-50 and 1-for-100 at a special meeting on October 28, 2026. The board retains discretion on whether and when to implement the split, which is potentially linked to a future listing on a U.S. national securities exchange. No financial data or definitive timeline was provided.

Key Facts

  • Stockholders approved a reverse stock split with a ratio between 1-for-50 and 1-for-100.
  • Votes for the amendment: 219,026,236 for, 46,400,304 against, 221,869 abstain.
  • The board retains discretion to determine the exact ratio and whether to implement the split at all.
  • The board may abandon the reverse stock split entirely.
  • The press release mentions a potential listing on a U.S. national securities exchange as a possible consideration.
  • No fractional shares will be issued; cash payments will be made in lieu of fractional shares.
  • The company trades on OTCQB under the ticker MRMD.

Financial Impact

No financial figures disclosed; the reverse stock split would reduce share count by a factor of 50 to 100 if implemented, but no dollar amounts or market cap data were provided.

share countstock price per share

Risk Factors

  • Reverse stock split may not be implemented; board can abandon it.
  • Even if implemented, there is no assurance of meeting listing requirements or sustained price/liquidity improvement.
  • No financial data or guidance was provided in this filing.

Market Snapshot

Exchange
OTC
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001522767-26-000213
Exhibit: ex99110x28x26specialmeetin.htm0001522767-26-000213
Document: 0001522767-26-000213-index-headers.html0001522767-26-000213
Document: 0001522767-26-000213-index.html0001522767-26-000213
Document: 0001522767-26-000213.txt0001522767-26-000213
3 reports for MRMD
Performance horizon
Filters
Rows
Reports for MRMD, sortable and filterable
TypeNow
Oct 29, 2026
3d ago
8-K
NEUTRAL ★ 3/10
$0.0530awaiting T+20awaiting T+20$0.0510 (−3.77%)
May 13, 2026
24w ago
8-K
NEUTRAL ★ 4/10
$0.0820 $0.0690▼ −15.85%▼ −15.00%$0.0510 (−37.80%)
Mar 11, 2026
33w ago
8-K
NEUTRAL ★ 4/10
$0.0770 $0.0700▼ −9.09%▼ −11.07%$0.0510 (−33.77%)
Showing 3 of 3

US Market Status

Market Closed · Opens Mon (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 29, 2026